Ceryvyn Therapeutics Limited CYVNY
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 79.04% | 79.08% | 270.22% | 265.02% | 72.97% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -13.01% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 118.55% | 118.52% | -495.11% | -483.04% | -410.79% |
| Change in Net Operating Assets | 82.08% | 82.11% | -- | -- | -178.78% |
| Cash from Operations | 97.84% | 97.84% | 91.08% | 91.36% | 3.83% |
| Capital Expenditure | -- | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | 100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 100.00% | -36,236.47% | -36,236.47% | -61.76% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 100.00% | 100.00% | -160.28% | -158.44% | -103.14% |
| Foreign Exchange rate Adjustments | -114.20% | -114.18% | -99.85% | -99.85% | -16.41% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 97.48% | 97.49% | 11.83% | 14.53% | -171.73% |